Search results

Skip to results

Type

Status

Last updated

Showing 1 to 15 of 16 results for ofatumumab

  1. Ofatumumab for treating relapsing multiple sclerosis (TA699)

    Evidence-based recommendations on ofatumumab (Kesimpta) for treating relapsing–remitting multiple sclerosis in adults with active disease defined by clinical or imaging features.

    Technology appraisal guidance
    Published
    19 May 2021
    View recommendations

    Sections for TA699

  2. Idelalisib with ofatumumab for treating chronic lymphocytic leukaemia (terminated appraisal) (TA469)

    NICE is unable to make a recommendation about the use in the NHS of idelalisib with ofatumumab for treating chronic lymphocytic leukaemia because no evidence submission was received from Gilead Sciences.

    Technology appraisal guidance
    Published
    23 August 2017

    Sections for TA469

  3. Ublituximab for treating relapsing multiple sclerosis (TA1025)

    Evidence-based recommendations on ublituximab (Briumvi) for treating relapsing multiple sclerosis in adults.

    Technology appraisal guidance
    Published
    18 December 2024
    View recommendations

    Sections for TA1025

  4. Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation (TA429)

    Evidence-based recommendations on ibrutinib (Imbruvica) for treating chronic lymphocytic leukaemia in adults.

    Technology appraisal guidance
    Published
    25 January 2017
    View recommendations

    Sections for TA429

  5. Cladribine for treating active relapsing forms of multiple sclerosis (TA1053)

    Evidence-based recommendations on cladribine (Mavenclad) for treating active relapsing forms of multiple sclerosis in adults.

    Technology appraisal guidance
    Published
    15 April 2025
    View recommendations

    Sections for TA1053

  6. Natalizumab (originator and biosimilar) for treating highly active relapsing–remitting multiple sclerosis after disease-modifying therapy [ID6369]

    In development [GID-TA10977] Expected publication date: 13 August 2025

    Technology appraisal guidance
    In development

  7. Idelalisib for treating chronic lymphocytic leukaemia (TA359)

    Evidence-based recommendations on idelalisib (Zydelig) for treating chronic lymphocytic leukaemia in adults.

    Technology appraisal guidance
    Published
    28 October 2015
    View recommendations

    Sections for TA359

  8. Ofatumumab for the maintenance treatment of relapsed chronic lymphocytic leukaemia [ID732]

    Discontinued [GID-TAG482]

    Technology appraisal guidance
    Discontinued

  9. Ofatumumab (Arzerra) in combination with chemotherapy for follicular lymphoma; second line - refractory to rituximab [ID1487]

    Discontinued [GID-TA10437]

    Technology appraisal guidance
    Discontinued

  10. Ofatumumab with chemotherapy for treating chronic lymphocytic leukaemia (terminated appraisal) (TA470)

    This advice has been withdrawn because Novartis has discontinued ofatumumab (Arzerra). Ofatumumab will continue to be available for people who need it. Contact Clinigen at managedacess@clinigengroup.com or 01932 842100 for details.

    Technology appraisal guidance
    Published
    23 August 2017

  11. Ofatumumab in combination with chlorambucil or bendamustine for untreated chronic lymphocytic leukaemia (TA344)

    This guidance has been withdrawn because Novartis has discontinued ofatumumab (Arzerra). Ofatumumab will continue to be available for people who need it. Contact Clinigen at managedacess@clinigengroup.com or 01932 842100 for details.

    Technology appraisal guidance
    Published
    2 June 2015

  12. Ofatumumab for the treatment of chronic lymphocytic leukaemia refractory to fludarabine and alemtuzumab (TA202)

    This guidance has been withdrawn because Novartis has discontinued ofatumumab (Arzerra). Ofatumumab will continue to be available for people who need it. Contact Clinigen at managedacess@clinigengroup.com or 01932 842100 for details.

    Technology appraisal guidance
    Published
    27 October 2010

  13. Ponesimod for treating relapsing–remitting multiple sclerosis (TA767)

    Evidence-based recommendations on ponesimod (Ponvory) for treating relapsing–remitting multiple sclerosis in adults.

    Technology appraisal guidance
    Published
    2 February 2022
    View recommendations

    Sections for TA767

  14. Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia (TA343)

    Evidence-based recommendations on obinutuzumab (Gazyvaro) with chlorambucil for untreated chronic lymphocytic leukaemia in adults.

    Technology appraisal guidance
    Published
    2 June 2015
    View recommendations

    Sections for TA343

  15. icobrain ms for active relapsing–remitting multiple sclerosis (MIB291)

    NICE has developed a medtech innovation briefing (MIB) on icobrain ms for active relapsing–remitting multiple sclerosis .

    Medtech innovation briefing
    Published
    29 March 2022